GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » Notes Receivable

Ectin Research AB (XSAT:ECTIN B) Notes Receivable : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB Notes Receivable?

Ectin Research AB's Notes Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Ectin Research AB Notes Receivable Historical Data

The historical data trend for Ectin Research AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB Notes Receivable Chart

Ectin Research AB Annual Data
Trend Aug19 Aug20 Dec22 Dec23
Notes Receivable
- - - -

Ectin Research AB Quarterly Data
Aug19 Aug20 Mar21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ectin Research AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Ectin Research AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ectin Research AB (XSAT:ECTIN B) Business Description

Traded in Other Exchanges
N/A
Address
Pepparedsleden 1, Molndal, SWE, 431 83
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines